Cargando…

S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma

Detalles Bibliográficos
Autores principales:	Liu, Chengming, Zheng, Sufei, Lu, Zhiliang, Wang, Zhanyu, Wang, Sihui, Feng, Xiaoli, Wang, Yan, Sun, Nan, He, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584899/ https://www.ncbi.nlm.nih.gov/pubmed/36266269 http://dx.doi.org/10.1038/s41392-022-01196-4

Ejemplares similares

S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis
por: Lu, Zhiliang, et al.
Publicado: (2021)

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

TGF-β-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2
por: Wang, Feng, et al.
Publicado: (2021)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Liu, Chengming, et al.
Publicado: (2021)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma
por: Liu, Chengming, et al.
Publicado: (2021)

A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma
por: Liu, Chengming, et al.
Publicado: (2021)

Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state
por: Huang, Jianbing, et al.
Publicado: (2020)

The immunosuppressive microenvironment and immunotherapy in human glioblastoma
por: Zhang, Xuehua, et al.
Publicado: (2022)

Role of the immunosuppressive microenvironment in immunotherapy
por: Tormoen, Garth W., et al.
Publicado: (2018)

cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment
por: Mishra, Sanjay, et al.
Publicado: (2022)

ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells
por: lei, Yuanyuan, et al.
Publicado: (2020)

Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy
por: Wang, Tingting, et al.
Publicado: (2022)

S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy
por: Li, Jianjie, et al.
Publicado: (2022)

The average copy number variation (CNVA) of chromosome fragments is a potential surrogate for tumor mutational burden in predicting responses to immunotherapy in non‐small‐cell lung cancer
por: Lei, Yuanyuan, et al.
Publicado: (2021)

PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
por: Mao, Shuangshuang, et al.
Publicado: (2019)

Oxygen-carrying nanoplatform to reprogram tumor immunosuppressive microenvironment and enhance photothermal-immunotherapy
por: Huang, Ju, et al.
Publicado: (2023)

Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer
por: Mao, Shuangshuang, et al.
Publicado: (2020)

BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
por: Liu, Wei, et al.
Publicado: (2022)

Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
por: Zhang, Yalei, et al.
Publicado: (2021)

The TGFβ-Induced Long Non-coding RNA TBULC Promotes the Invasion and Migration of Non-small Cell Lung Cancer Cells and Indicates Poor Prognosis
por: Zheng, Sufei, et al.
Publicado: (2019)

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance
por: Yang, Minglei, et al.
Publicado: (2022)

Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1
por: Mao, Shuangshuang, et al.
Publicado: (2021)

Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer
por: Otegui, Nerea, et al.
Publicado: (2023)

The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer
por: Lei, Yuanyuan, et al.
Publicado: (2020)

Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective
por: Li, Ying, et al.
Publicado: (2023)

Prediction of lung squamous cell carcinoma immune microenvironment and immunotherapy efficiency with pyroptosis-derived genes
por: Deng, Xiaheng, et al.
Publicado: (2022)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein–Barr Virus-Associated Malignancies
por: Zheng, Xueyi, et al.
Publicado: (2022)

Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment
por: Franson, Andrea, et al.
Publicado: (2022)

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
por: Xu, Yanyan, et al.
Publicado: (2022)

Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response
por: Currenti, Jennifer, et al.
Publicado: (2023)

Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy
por: Shafqat, Areez, et al.
Publicado: (2023)

S100A11: A Potential Carcinogen and Prognostic Marker That Correlates with the Immunosuppressive Microenvironment in Pan-Cancer
por: Ji, Xiaozhen, et al.
Publicado: (2023)

Single-cell analysis reveals the potential mechanisms of pyrotinib resistance in non-small cell lung cancer
por: Wang, Xinfeng, et al.
Publicado: (2023)

Emerging role of RNA sensors in tumor microenvironment and immunotherapy
por: Yang, Rui, et al.
Publicado: (2022)

Immunosuppressive activity is attenuated by Astragalus polysaccharides through remodeling the gut microenvironment in melanoma mice
por: Ding, Guiqing, et al.
Publicado: (2021)

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
por: Cui, Xin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ch8heibu650ms6uitu3ba92gf4